Fig. 1 · Structure

Documents & Downloads

Nepicastat (free base) (SYN-117)

Cat. No. A10637 CAS 173997-05-2

dopamine beta-hydroxylase inhibitor

Nepicastat is an inhibitor of dopamine beta-hydroxylase, an enzyme that catalyzes the conversion of dopamine to norepinephrine.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vivo Studies

Nepicastat (free base) reduced cortical NE levels in Dbh +/− mice compared with saline vehicle. In DAT-KO mice, treatment reduced PFC tissue NE levels and elevated DA levels without altering 5-HT levels. In LLC-implanted mice exposed to CIH, treatment significantly inhibited CIH-induced tumor growth and decreased CIH-induced serum NE and EPI levels compared with CIH plus vehicle. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Nepicastat reduces cortical NE in Dbh +/− mice

Animal study · Dbh +/− mice [1]

Dbh +/− mice received nepicastat by i.p. injection. Cortical NE levels were reduced compared with saline vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cortical NE levelscortical NE levels 50 mg/kg, i.p.; 3 times, each injection two hours apart: ∼75%[1]

Conditions shared by the study groups

Route
i.p.
Treatment course
3 times, each injection two hours apart
Vehicle
sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nepicastat (free base) 50 mg/kgsaline (10 ml/kg, i.p.)∼75%) reduction in cortical NE levels (vehicle, 0.18±0.01 ng/mg tissue, n = 12; nepicastat, 0.04±0.01 ng/mg tissue, n = 13, P<0.0001)[1]
Nepicastat (free base) 50 mg/kg
Model: Dbh +/− mice
Methods and source locations

Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Drugs (S15); Materials and Methods > Quantification of Norepinephrine Levels (S22); Results > Nepicastat Reduces Brain NE content in Dbh +/− Mice (S57, S58)

cortical NE levels: cortical NE levels; comparator: saline (10 ml/kg, i.p.) — Materials and Methods > Quantification of Norepinephrine Levels (S22); Results > Nepicastat Reduces Brain NE content in Dbh +/− Mice (S58)

Nepicastat (free base) 50 mg/kg · Materials and Methods > Quantification of Norepinephrine Levels (S22); Results > Nepicastat Reduces Brain NE content in Dbh +/− Mice (S58)

Nepicastat and CIH-Induced Tumor Growth in LLC-Implanted Mice

Animal study · 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group [2]

In LLC-implanted mice exposed to CIH, Nepicastat (free base) administered by oral gavage significantly inhibited CIH-induced tumor growth compared with CIH plus vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumeReported result either propranolol or nepicastat significantly inhibited the CIH-induced tumor growth (P < 0.001)[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
Prior to daily exposure; 4 weeks
Vehicle
carboxymethylcellulose sodium (CMC-Na, Sangon Biotech)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nepicastat (free base) 10 mg/kg body weightCIH plus vehicle (CIH + Vehi)either propranolol or nepicastat significantly inhibited the CIH-induced tumor growth (P < 0.001)[2]
Nepicastat (free base) 10 mg/kg body weight
Model: 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group
Methods and source locations

Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals and chronic intermittent hypoxia exposure (S8, S12, S16, S19, S20, S22, S23); Methods > Serum and tissue sample preparation from LLC-implanted mice (S28); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S68)

Tumor volume: Tumor volume; comparator: CIH plus vehicle (CIH + Vehi) — Methods > Animals and chronic intermittent hypoxia exposure (S22); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S68)

Nepicastat (free base) 10 mg/kg body weight · Methods > Animals and chronic intermittent hypoxia exposure (S19, S23); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S68)

Nepicastat alters PFC catecholamine levels in DAT-KO mice

Animal study · DAT-KO mice [3]

HPLC analysis of PFC tissue from DAT-KO mice systemically injected with nepicastat showed reduced tissue NE levels and elevated tissue DA levels without altering 5-HT levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NE, DA or 5-HT levels by HPLCReported result 40 mg/kg, i.p.: HPLC analysis of PFC tissue from DAT-KO mice systemically injected with nepicastat showed reduced tissue NE levels and elevated tissue DA levels without altering 5-HT levels.[3]

Conditions shared by the study groups

Route
i.p. injection
Vehicle
1% DMSO and 10% hydroxypropyl-cyclodextrin (Sigma) and brought up to volume with saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nepicastat (free base) 40 mg/kgvehicle (veh) treated40 mg/kg, i.p.: HPLC analysis of PFC tissue from DAT-KO mice systemically injected with nepicastat showed reduced tissue NE levels and elevated tissue DA levels without altering 5-HT levels.[3]
Nepicastat (free base) 40 mg/kg
Model: DAT-KO mice
Reported limits: Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results (S50, S51, S58, S59); Methods > Animals and drugs (S66)

NE, DA or 5-HT levels by HPLC: NE, DA or 5-HT levels by HPLC; comparator: vehicle (veh) treated — Results (S50, S51, S58)

Nepicastat (free base) 40 mg/kg · Results (S50, S51, S58)

Nepicastat and Serum NE and EPI in CIH-Exposed Mice

Animal study · 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group [2]

In LLC-implanted mice exposed to CIH, Nepicastat (free base) administered by oral gavage decreased CIH-induced serum NE and EPI levels compared with CIH plus vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ELISA results of NE and EPI in mouse serumReported result Administration of nepicastat decreased the levels of NE (P < 0.05) and EPI induced by CIH.[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
Prior to daily exposure; 4 weeks
Vehicle
carboxymethylcellulose sodium (CMC-Na, Sangon Biotech)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nepicastat (free base) 10 mg/kg body weightCIH plus vehicle (CIH + Vehi)Administration of nepicastat decreased the levels of NE (P < 0.05) and EPI induced by CIH.[2]
Nepicastat (free base) 10 mg/kg body weight
Model: 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group
Methods and source locations

Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals and chronic intermittent hypoxia exposure (S8, S12, S16, S19, S20, S23); Methods > Serum and tissue sample preparation from LLC-implanted mice (S28); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S70, S71, S83)

ELISA results of NE and EPI in mouse serum: ELISA results of NE and EPI in mouse serum; comparator: CIH plus vehicle (CIH + Vehi) — Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S71, S83)

Nepicastat (free base) 10 mg/kg body weight · Methods > Animals and chronic intermittent hypoxia exposure (S19, S23); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S71)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 173997-05-2
Applications dopamine beta-hydroxylase inhibitor
Formula C14H15F2N3S
Molecular Weight 295.4
Synonyms RS-25560-197; SYN-117
SMILES
C1CC2=C(C=C(C=C2C[C@H]1N3C(=CNC3=S)CN)F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 61 mg/mL (183.83 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Gaval-Cruz M, Liles LC, Iuvone PM, et al. Chronic inhibition of dopamine β-hydroxylase facilitates behavioral responses to cocaine in mice. PLoS One (2012). PMID: 23209785 DOI: 10.1371/journal.pone.0050583 Source material
  2. [2] Sun J, Jia X, Zhang Z, et al. Role of β-adrenergic signaling and the NLRP3 inflammasome in chronic intermittent hypoxia-induced murine lung cancer progression. Respir Res (2024). PMID: 39342317 DOI: 10.1186/s12931-024-02969-x Source material
  3. [3] Harris SS, Green SM, Kumar M, et al. A role for cortical dopamine in the paradoxical calming effects of psychostimulants. Sci Rep (2022). PMID: 35210489 DOI: 10.1038/s41598-022-07029-2 Source material

Added to your cart

View Cart Checkout
Loading...